ParAllele Press Release
South San Francisco, CA, February 11, 2002 - ParAllele BioScience, whose "lab in a tube"(TM) technologies are enabling large scale genomic analysis and contributing to the "HapMap" project, has strengthened the company's Board of Directors with the addition of André F. Marion. Mr. Marion was formerly the President of Perkin Elmer Corporation's Applied Biosystems Division.
Mr. Marion joins ParAllele directors: Tom Willis, Ph.D., ParAllele's President and Chief Executive Officer; Ron Davis, Ph.D., Director of the Stanford Genome Technology Center and a company co-founder; Francesco DeRubertis, Ph.D., a Partner at Index Ventures; Jonathan MacQuitty, Ph.D., President of Abingworth Management, Inc.; Camille Samuels Pearson, Managing Director at Versant Ventures; Mostafa Ronaghi, Ph.D., a company co-founder; and Gregory T. Went, Ph.D., a co-founder of CuraGen, and CEO & Chairman of two early-stage biotechnology companies. The recent appointment of Mr. Marion brings the total number of ParAllele Board members to eight.
"ParAllele has made significant strides developing and commercializing revolutionary tools designed for truly comprehensive genomic research in its first year of operation. With the support and expertise of our Board, ParAllele has been able to accomplish and exceed all of our initial scientific, operational and commercial goals," said Dr. Willis. "I am pleased to welcome André Marion to our Board. His history of building ABI into a highly successful technology platform company, as well as his varied experience working with early-stage life sciences companies, will be invaluable to ParAllele as we continue to build our commercial infrastructure."
"I am pleased to join ParAllele at this promising stage in the company's growth," said Mr. Marion. "ParAllele is rapidly creating revolutionary technologies that promise to facilitate a new era of genomic discovery by enabling powerful and comprehensive multiplexed discovery and analysis of both rare alleles and single nucleotide polymorphisms."
André F. Marion was one of the founders of Applied Biosystems, Inc. He served as Chairman, Chief Executive Officer and President for several years until the company's merger with Perkin Elmer Corporation. In 1995 he retired from the Perkin Elmer Corporation as the President of its Applied Biosystems Division. Prior to the founding of Applied Biosystems, Mr. Marion held various research and development management positions with Hewlett-Packard Corporation. Mr. Marion currently serves as a director on the boards of several companies, including Aclara BioSciences, Corp., Molecular Devices Corp., Cygnus, Inc. and Applied Imaging Corp. A native of France, he holds an engineering degree from the French Ecole Nationale Supérieures d'Ingénieurs Arts et Métiers in both mechanical and electronic engineering.
About ParAllele BioscienceParAllele BioScience is developing and commercializing new products and technologies that will accelerate healthcare breakthroughs. By harnessing biochemical processes, ParAllele is creating highly multiplexed, compact, scalable solutions for genetics research. The company's current offerings include solutions for SNP discovery, genotyping, and variation scanning. ParAllele's customers and partners include leading pharmaceutical companies, academic research centers, life science instrumentation companies and the National Institutes of Health (NIH). The company was founded by a team of researchers from the Stanford Genome Technology Center and Uppsala University in 2001 and is presently headquartered in South San Francisco, California. Investors in the privately held company include Abingworth Management, Index Ventures, Mohr Davidow Ventures (MDV) and Versant Ventures. For more information about ParAllele, please visit the company's website at: parallelebio.com.
|
